CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CHEM-SCAN focuses on understanding cancer cell resistance to chemotherapy by developing new fluorescent probes to monitor metabolic changes at the single-cell level. This innovative platform aims to provide insights into personalized treatment strategies for chemoresistant tumors, enhancing cancer care.
The development of chemoresistance, i.e. the ability of cancer cells to evade treatment, has become a major challenge for current cancer therapy and significantly contributes to most tumor relapses and deaths.
Changes in the way how sub-populations of cancer cells process metabolites have been identified as an indication of tumor chemoresistance: multiple different metabolites were found and identified in several chemoresistant tumors, which are attributed to facilitate tumor cell survival under…
UNIVERSITAET BIELEFELD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Berlin
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Belgium, Leuven
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, Paris
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Austria, Wien
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
